ProteinLogic Appoints Dr Edward Gibson as Non-Executive Director

CAMBRIDGE, UK (2018-09-01) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Edward Gibson as Non-Executive Director.

Dr Gibson holds a holds a degree in Chemistry from Bristol University, and a PhD in Biochemistry from Oxford University, where he also performed postdoctoral research. Since then, he has held a number of senior leadership roles with Bristol-Myers Squibb, focusing on commercialization and lifecycle management within the company’s oncology department, rising to becoming a member of the European oncology steering committee. He then went on to become Senior Director for New Product Strategy and EU commercialization with AVEO, as a member of the senior executive team. Since 2013, he has held the role of Global Pharma Key Opinion Leader for the Korean Health Industry Development Institute, and has devoted himself in the development of solutions to complex issues in healthcare access a CEO of an independent consultancy.

Dr Gibson commented: “Joining the board at this critical time in the development of ProteinLogic is an extremely exciting opportunity. I am looking forward to working with the diverse and knowledgeable team members in developing and delivering credible, commercial diagnostic solutions to complex disease problems. Starting with the acute need in identifying cases of Active Tuberculosis.”

Dr Nicolas Huber, CEO of ProteinLogic, commented: “I am very excited to welcome Dr Gibson to the board of ProteinLogic. He brings a wealth of knowledge in the biotech industry, including in markets in which ProteinLogic has keen interest. With his extensive expertise in the commercialization of novel products in the field, he will be instrumental in helping the company define the most direct and profitable routes to market for our unique Immiprint diagnostic for the ruling-out of Active Tuberculosis, maximizing the value of our solution. Dr Gibson’s  joining strengthens the board of the company with unique commercial know-how that is of paramount importance to our success. I am personally very much looking forward to closely collaborating with him in the near future.”